Based on interim data from a late-stage trial, Moderna said it experimental vaccine is 94.5% effective in preventing Covid-19, becoming the second US drugmaker to report results that far exceed expectations.
Moderna's interim analysis was based on 95 infections among trial participants who received the vaccine . . .
Please Login to read all contents for free.